RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma

Ann C. Mladek; Huihuang Yan; Shulan Tian; Paul A. Decker; Danielle M. Burgenske; Katrina Bakken; Zeng Hu; Lihong He; Margaret A. Connors; Brett L. Carlson; Jonathan Wilson; Archana Bommi-Reddy; Andy Conery; Jeanette E. Eckel-Passow; Jann N. Sarkaria; Gaspar J. Kitange

doi:10.1093/neuonc/noac051

RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma

Ann C. Mladek, Huihuang Yan, Shulan Tian, Paul A. Decker, Danielle M. Burgenske, Katrina Bakken, Zeng Hu, Lihong He, Margaret A. Connors, Brett L. Carlson, Jonathan Wilson, Archana Bommi-Reddy, Andy Conery, Jeanette E. Eckel-Passow, Jann N. Sarkaria, Gaspar J. Kitange

Pharmaceutics

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

BACKGROUND: RBBP4 activates transcription by histone acetylation, but the partner histone acetyltransferases are unknown. Thus, we investigated the hypothesis that RBBP4 interacts with p300 in a complex in glioblastoma (GBM).

METHODS: shRNA silencing of RBBP4 or p300 and RNAseq was used to identify genes co-regulated by RBBP4 and p300 in GBM43 patient-derived xenograft (PDX). RBBP4/p300 complex was demonstrated using proximity ligation assay (PLA) and ChIPseq delineated histone H3 acetylation and RBBP4/p300 complex binding in promoters/enhancers. Temozolomide (TMZ)-induced DNA double strand breaks (DSBs) were evaluated by γ-H2AX and proliferation by CyQuant and live cell monitoring assays. In vivo efficacy was based on survival of mice with orthotopic tumors.

RESULTS: shRBBP4 and shp300 downregulated 4768 genes among which 1485 (31%) were commonly downregulated by both shRNAs, while upregulated genes were 2484, including 863 (35%) common genes. The pro-survival genes were the top-ranked among the downregulated genes, including C-MYC. RBBP4/p300 complex was demonstrated in the nucleus, and shRBBP4 or shp300 significantly sensitized GBM cells to TMZ compared to the control shNT in vitro (P < .05). Moreover, TMZ significantly prolonged the survival of mice bearing GBM22-shRBBP4 orthotopic tumors compared with control shNT tumors (median shNT survival 52 days vs. median shRBBP4 319 days; P = .001). CREB-binding protein (CBP)/p300 inhibitor CPI-1612 suppressed H3K27Ac and RBBP4/p300 complex target proteins, including C-MYC, and synergistically sensitized TMZ in vitro. Pharmacodynamic evaluation confirmed brain penetration by CPI-1612 supporting further investigation to evaluate efficacy to sensitize TMZ.

CONCLUSIONS: RBBP4/p300 complex is present in GBM cells and is a potential therapeutic target.

Original language	English (US)
Pages (from-to)	1261-1272
Number of pages	12
Journal	Neuro-Oncology
Volume	24
Issue number	8
DOIs	https://doi.org/10.1093/neuonc/noac051
State	Published - Aug 1 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.

Keywords

glioblastoma
histone acetylation
RBB4/p300 complex
temozolomide
Retinoblastoma-Binding Protein 4/genetics
Promoter Regions, Genetic
E1A-Associated p300 Protein/genetics
Cell Survival
Humans
Drug Resistance, Neoplasm
Xenograft Model Antitumor Assays
Glioblastoma/drug therapy
Animals
Cell Line, Tumor
Mice
Acetylation
Temozolomide/pharmacology
Brain Neoplasms/drug therapy

PubMed: MeSH publication types

Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1093/neuonc/noac051

Find It

Find It at U of M Libraries

Cite this

Mladek, A. C., Yan, H., Tian, S., Decker, P. A., Burgenske, D. M., Bakken, K., Hu, Z., He, L., Connors, M. A., Carlson, B. L., Wilson, J., Bommi-Reddy, A., Conery, A., Eckel-Passow, J. E., Sarkaria, J. N., & Kitange, G. J. (2022). RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. Neuro-Oncology, 24(8), 1261-1272. https://doi.org/10.1093/neuonc/noac051

Mladek, AC, Yan, H, Tian, S, Decker, PA, Burgenske, DM, Bakken, K, Hu, Z, He, L, Connors, MA, Carlson, BL, Wilson, J, Bommi-Reddy, A, Conery, A, Eckel-Passow, JE, Sarkaria, JN & Kitange, GJ 2022, 'RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma', Neuro-Oncology, vol. 24, no. 8, pp. 1261-1272. https://doi.org/10.1093/neuonc/noac051

@article{c9e61aa1173b457f8265847f5d307d43,

title = "RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma",

abstract = "BACKGROUND: RBBP4 activates transcription by histone acetylation, but the partner histone acetyltransferases are unknown. Thus, we investigated the hypothesis that RBBP4 interacts with p300 in a complex in glioblastoma (GBM).METHODS: shRNA silencing of RBBP4 or p300 and RNAseq was used to identify genes co-regulated by RBBP4 and p300 in GBM43 patient-derived xenograft (PDX). RBBP4/p300 complex was demonstrated using proximity ligation assay (PLA) and ChIPseq delineated histone H3 acetylation and RBBP4/p300 complex binding in promoters/enhancers. Temozolomide (TMZ)-induced DNA double strand breaks (DSBs) were evaluated by γ-H2AX and proliferation by CyQuant and live cell monitoring assays. In vivo efficacy was based on survival of mice with orthotopic tumors.RESULTS: shRBBP4 and shp300 downregulated 4768 genes among which 1485 (31%) were commonly downregulated by both shRNAs, while upregulated genes were 2484, including 863 (35%) common genes. The pro-survival genes were the top-ranked among the downregulated genes, including C-MYC. RBBP4/p300 complex was demonstrated in the nucleus, and shRBBP4 or shp300 significantly sensitized GBM cells to TMZ compared to the control shNT in vitro (P < .05). Moreover, TMZ significantly prolonged the survival of mice bearing GBM22-shRBBP4 orthotopic tumors compared with control shNT tumors (median shNT survival 52 days vs. median shRBBP4 319 days; P = .001). CREB-binding protein (CBP)/p300 inhibitor CPI-1612 suppressed H3K27Ac and RBBP4/p300 complex target proteins, including C-MYC, and synergistically sensitized TMZ in vitro. Pharmacodynamic evaluation confirmed brain penetration by CPI-1612 supporting further investigation to evaluate efficacy to sensitize TMZ.CONCLUSIONS: RBBP4/p300 complex is present in GBM cells and is a potential therapeutic target.",

keywords = "glioblastoma, histone acetylation, RBB4/p300 complex, temozolomide, Retinoblastoma-Binding Protein 4/genetics, Promoter Regions, Genetic, E1A-Associated p300 Protein/genetics, Cell Survival, Humans, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Glioblastoma/drug therapy, Animals, Cell Line, Tumor, Mice, Acetylation, Temozolomide/pharmacology, Brain Neoplasms/drug therapy",

author = "Mladek, {Ann C.} and Huihuang Yan and Shulan Tian and Decker, {Paul A.} and Burgenske, {Danielle M.} and Katrina Bakken and Zeng Hu and Lihong He and Connors, {Margaret A.} and Carlson, {Brett L.} and Jonathan Wilson and Archana Bommi-Reddy and Andy Conery and Eckel-Passow, {Jeanette E.} and Sarkaria, {Jann N.} and Kitange, {Gaspar J.}",

year = "2022",

month = aug,

day = "1",

doi = "10.1093/neuonc/noac051",

language = "English (US)",

volume = "24",

pages = "1261--1272",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma

AU - Mladek, Ann C.

AU - Yan, Huihuang

AU - Tian, Shulan

AU - Decker, Paul A.

AU - Burgenske, Danielle M.

AU - Bakken, Katrina

AU - Hu, Zeng

AU - He, Lihong

AU - Connors, Margaret A.

AU - Carlson, Brett L.

AU - Wilson, Jonathan

AU - Bommi-Reddy, Archana

AU - Conery, Andy

AU - Eckel-Passow, Jeanette E.

AU - Sarkaria, Jann N.

AU - Kitange, Gaspar J.

PY - 2022/8/1

Y1 - 2022/8/1

N2 - BACKGROUND: RBBP4 activates transcription by histone acetylation, but the partner histone acetyltransferases are unknown. Thus, we investigated the hypothesis that RBBP4 interacts with p300 in a complex in glioblastoma (GBM).METHODS: shRNA silencing of RBBP4 or p300 and RNAseq was used to identify genes co-regulated by RBBP4 and p300 in GBM43 patient-derived xenograft (PDX). RBBP4/p300 complex was demonstrated using proximity ligation assay (PLA) and ChIPseq delineated histone H3 acetylation and RBBP4/p300 complex binding in promoters/enhancers. Temozolomide (TMZ)-induced DNA double strand breaks (DSBs) were evaluated by γ-H2AX and proliferation by CyQuant and live cell monitoring assays. In vivo efficacy was based on survival of mice with orthotopic tumors.RESULTS: shRBBP4 and shp300 downregulated 4768 genes among which 1485 (31%) were commonly downregulated by both shRNAs, while upregulated genes were 2484, including 863 (35%) common genes. The pro-survival genes were the top-ranked among the downregulated genes, including C-MYC. RBBP4/p300 complex was demonstrated in the nucleus, and shRBBP4 or shp300 significantly sensitized GBM cells to TMZ compared to the control shNT in vitro (P < .05). Moreover, TMZ significantly prolonged the survival of mice bearing GBM22-shRBBP4 orthotopic tumors compared with control shNT tumors (median shNT survival 52 days vs. median shRBBP4 319 days; P = .001). CREB-binding protein (CBP)/p300 inhibitor CPI-1612 suppressed H3K27Ac and RBBP4/p300 complex target proteins, including C-MYC, and synergistically sensitized TMZ in vitro. Pharmacodynamic evaluation confirmed brain penetration by CPI-1612 supporting further investigation to evaluate efficacy to sensitize TMZ.CONCLUSIONS: RBBP4/p300 complex is present in GBM cells and is a potential therapeutic target.

AB - BACKGROUND: RBBP4 activates transcription by histone acetylation, but the partner histone acetyltransferases are unknown. Thus, we investigated the hypothesis that RBBP4 interacts with p300 in a complex in glioblastoma (GBM).METHODS: shRNA silencing of RBBP4 or p300 and RNAseq was used to identify genes co-regulated by RBBP4 and p300 in GBM43 patient-derived xenograft (PDX). RBBP4/p300 complex was demonstrated using proximity ligation assay (PLA) and ChIPseq delineated histone H3 acetylation and RBBP4/p300 complex binding in promoters/enhancers. Temozolomide (TMZ)-induced DNA double strand breaks (DSBs) were evaluated by γ-H2AX and proliferation by CyQuant and live cell monitoring assays. In vivo efficacy was based on survival of mice with orthotopic tumors.RESULTS: shRBBP4 and shp300 downregulated 4768 genes among which 1485 (31%) were commonly downregulated by both shRNAs, while upregulated genes were 2484, including 863 (35%) common genes. The pro-survival genes were the top-ranked among the downregulated genes, including C-MYC. RBBP4/p300 complex was demonstrated in the nucleus, and shRBBP4 or shp300 significantly sensitized GBM cells to TMZ compared to the control shNT in vitro (P < .05). Moreover, TMZ significantly prolonged the survival of mice bearing GBM22-shRBBP4 orthotopic tumors compared with control shNT tumors (median shNT survival 52 days vs. median shRBBP4 319 days; P = .001). CREB-binding protein (CBP)/p300 inhibitor CPI-1612 suppressed H3K27Ac and RBBP4/p300 complex target proteins, including C-MYC, and synergistically sensitized TMZ in vitro. Pharmacodynamic evaluation confirmed brain penetration by CPI-1612 supporting further investigation to evaluate efficacy to sensitize TMZ.CONCLUSIONS: RBBP4/p300 complex is present in GBM cells and is a potential therapeutic target.

KW - glioblastoma

KW - histone acetylation

KW - RBB4/p300 complex

KW - temozolomide

KW - Retinoblastoma-Binding Protein 4/genetics

KW - Promoter Regions, Genetic

KW - E1A-Associated p300 Protein/genetics

KW - Cell Survival

KW - Humans

KW - Drug Resistance, Neoplasm

KW - Xenograft Model Antitumor Assays

KW - Glioblastoma/drug therapy

KW - Animals

KW - Cell Line, Tumor

KW - Mice

KW - Acetylation

KW - Temozolomide/pharmacology

KW - Brain Neoplasms/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85135419747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135419747&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noac051

DO - 10.1093/neuonc/noac051

M3 - Article

C2 - 35231103

AN - SCOPUS:85135419747

SN - 1522-8517

VL - 24

SP - 1261

EP - 1272

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 8

ER -

RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this